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Background: The rate of microscopic incomplete resections of gastrointestinal cancers including pancreatic cancer
has not changed considerably over the past years. Future intra-operative applications of tissue tolerable plasmas
(TTP) could help to address this problem. Plasma is generated by feeding energy, like electrical discharges, to gases.
The development of non-thermal atmospheric plasmas displaying spectra of temperature within or just above
physiological ranges allows biological or medical applications of plasmas.
Methods: We have investigated the effects of tissue tolerable plasmas (TTP) on the human pancreatic cancer cell
line Colo-357 and PaTu8988T and the murine cell line 6606PDA in vitro (Annexin-V-FITC/DAPI-Assay and propidium
iodide DNA staining assay) as well as in the in vivo tumour chorio-allantoic membrane (TUM-CAM) assay using
Colo-357.
Results: TTP of 20 seconds (s) induced a mild elevation of an experimental surface temperature of 23.7 degree
Celsius up to 26.63+/−0.40 degree Celsius. In vitro TTP significantly (p=0.0003) decreased cell viability showing the
strongest effects after 20s TTP. Also, TTP effects increased over time levelling off after 72 hours (30.1+/−4.4% of
dead cells (untreated control) versus 78.0+/−9.6% (20s TTP)). However, analyzing these cells for apoptosis 10s TTP
revealed the largest proportion of apoptotic cells (34.8+/−7.2%, p=0.0009 versus 12.3+/−6.6%, 20s TTP) suggesting
non-apoptotic cell death in the majority of cells after 20s TTP. Using solid Colo-357 tumours in the TUM-CAM
model TUNEL-staining showed TTP-induced apoptosis up to a depth of tissue penetration (DETiP) of 48.8
+/−12.3μm (20s TTP, p<0.0001). This was mirrored by a significant (p<0.0001) reduction of Ki-67+ proliferating cells
(80.9+/−13.2% versus 37.7+/−14.6%, p<0.0001) in the top cell layers as well as typical changes on HE specimens.
The bottom cell layers were not affected by TTP.
Conclusions: Our data suggest possible future intra-operative applications of TTP to reduce microscopic residual
disease in pancreatic cancer resections. Further promising applications include other malignancies (central liver/lung
tumours) as well as synergistic effects combining TTP with chemotherapies. Yet, adaptations of plasma sources as
well as of the composition of effective components of TTP are required to optimize their synergistic apoptotic
actions.
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Figure 1 Plasma jet kINPen09 (Neoplas GmbH, Greifswald,
Germany) - application of TTP in vitro.
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The development of multimodal therapies for different
tumour entities along with highly specialized radical
tumour resections have greatly improved the outcomes
in many malignancies [1,2]. However, in gastrointestinal
cancers in general and in pancreatic cancer in particular
the rate of microscopic incomplete resections has not
changed considerably over the past few years. Fre-
quently, in pancreatic cancer surgeons are left in this di-
lemma of in situ remaining tumour cells [3,4]. The
future intra-operative application of tissue tolerable plas-
mas could help to address this problem in a clinical set-
ting. Special applicators of plasmas could help to destroy
microscopic residual tumour cells of retroperitoneal tis-
sues as well as on central coeliac and mesenteric vessels.
This could greatly increase radical resections improving
the prognosis of pancreatic cancer at the same time.
In physical sciences, the term “plasma” refers to the
forth state of matter [5]. It is generated by feeding en-
ergy, e.g. electrical discharges, to gases [6]. Plasma itself
consists of positively and negatively charged particles
(i.e. ions and electrons), free radicals, neutral and excited
atoms or molecules as well as photons. In all plasmas
supported by electric field electrons receive the external
energy much faster than the much heavier ions and have
the opportunity to heat up to several thousands of
degrees before their environment heats up [7].
In non-thermal plasma, cooling of ions and uncharged
molecules is more effective than energy transfer from
electrons and the gas remains at low temperature. In
thermal plasma, on the other hand, energy flux from
electrons to heavy particles equilibrates the energy flux
from heavy particles to the environment only when
temperature of heavy particles becomes almost equal to
the electron temperature [6] and [7]. The development
of non-thermal atmospheric plasmas displaying spectra
of temperature within or just above physiological ranges,
i.e. tissue tolerable plasmas (TTP), has made the use of
plasmas possible for biological or medical applications
[8,9]. This includes the utilization in living organisms.
First results on the compatibility and application of plas-
mas have been gained in the fields of dermatology as
well as hygiene and microbiology [10-14]. In addition,
initial reports on the efficacy of plasmas on tumours
have been published [6,15].
In this study, we have investigated the effects of tissue
tolerable plasmas (TTP) on the human pancreatic cancer
cell line Colo-357 in vitro as well as in the in vivo tumour
chorio-allantoic membrane assay (TUM-CAM assay).
Methods
Cell line and culture
The human pancreatic adenocarcinoma cell line Colo-
357 (established by Morgan et al. [16]) was maintainedin RPMI-1640 medium supplemented with 10% fetal calf
serum, 100 U/ml of penicillin and 100 μg/ml of strepto-
mycin (referred to as “complete medium”). In addition,
the murine pancreatic cancer cell line 6606PDA [17] and
the human pancreatic cancer cell line PaTu8988T [18]
were tested in vitro to exclude cell specific effects of TTP.
6606PDA cells were cultured in complete medium,
PaTu8988T cells were cultured in DMEM high glucose,
supplemented with 10% fetal calf serum, 100 U/ml of
penicillin and 100 μg/ml of streptomycin. Tissue culture
reagents were obtained from Gibco (Invitrogen, Carlsbad,
California, USA). Cell cultures were kept pathogen-free in
a humidified incubator at 37°C with 5% CO2. Cell cultures
were regularly tested for Mycoplasma species. They were
consistently negative for mycoplasma contamination.
Tissue tolerable plasma (TTP)
The plasma was generated with the atmospheric pres-
sure plasma jet kINPen09 (Neoplas GmbH, Greifswald,
Germany, CE certification No. 609.003.1, Figure 1) as
previously described [9] argon being the carrier gas. The
plasma was used in continuous mode with following set-
tings: gas flow 4 standard litres per minute (slm); supply
voltage Usupl. = 65 V DC (system power: 8W at 220V,
50/60Hz); frequency f = 1.1 MHz. In continuous mode
the plasma temperature was 45°C and the length of the
effluent plasma was 11 mm measured from the nozzle.
Measurement of temperature induction of TTP
The surface temperature of cell culture dishes was mea-
sured after 5, 10 and 20 seconds of TTP treatment using
a Voltcraft K102 digital thermometer (Conrad Electronic
SE, Hirschau, Germany) employing a paddle surface
probe with a miniature plug (B+B Thermo-Technik,
Donaueschingen, Germany). Measurements were repeated
10 times in each case.
Plasma treatment and detection of cell viability and
apoptosis in vitro
Colo-357 cells were grown to subconfluency, harvested
using a 0.05% trypsin solution, washed twice in PBS,
Figure 2 TUM-CAM (Colo-357) before and 48h after 10s TTP
treatment (asterisk: tumour; black arrow: supplying blood
vessel; white arrow: silicone ring).
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inserts (5mm plastic templates, self-made) were used in
12 well plates (BD Bioscience, Heidelberg, Germany) to
grow tumour cells for plasma treatment. 1x106 Colo-357
cells were added into cell culture inserts and grown in
complete medium for 24 hours. Then, the medium and
the plastic templates were removed leaving only a thin
liquid film of medium on the tumour cells. Plasma treat-
ment was carried out using the above described plasma
jet kINPen09. The plasma jet was applied for different
time periods, i.e. 5 seconds, 10 seconds, and 20 seconds.
The plume was guided randomly in a meandering course
across the tumour cells. To ensure optimal plasma
effects on the tumour cells the distance from the nozzle
to the tumour cells did not exceed 10 mm. One control
group was treated with argon gas only for 20 seconds;
one control group was left untreated. After treatment
cultures received fresh medium. Tumour cells were ana-
lyzed 1, 24, 48, and 72 hours following plasma treat-
ment. Analyses were performed using a propidium
iodide DNA staining assay, using the TREG-detection
kit (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany) for intracellular staining of FOXP3 (forkhead
box P3). After a 15 minute incubation step with the
permeabilization buffer cells were centrifuged and resus-
pended in 100 μl of this buffer adding 30 μl of RNase A
(1mg/ml, R4875, Sigma-Aldrich, Hamburg, Germany)
and 1 ml of binding buffer consisting of HBSS (Sigma-
Aldrich, Hamburg, Germany), 10% FCS (PAN™ Biotech
GmbH, Aidenbach, Germany) and 0.01 M HEPES
(Biochrom, Berlin, Germany). This was followed by 15
minutes of incubation at 37°C. Then, 200 μl of propi-
dium iodide (25μg/ml) were added, cells incubated for
30 minutes at room temperature and washed in binding
buffer. Cells were resuspended in 100 μl of binding buf-
fer followed by flow cytometric analyses. In a second test
an Annexin-V-FITC/DAPI-Assay was employed. Briefly,
tumour cells were released from the plastic surface with
300μl EDTA (10mM), washed in medium followed by
washing in binding buffer. Then, cells were resuspended
in 100μl of binding buffer adding 1 μl of FITC-Annexin-
V (BD Pharmingen, Heidelberg, Germany) followed by
30 minutes of incubation at 4°C. Afterwards, cells were
washed in binding buffer and resuspended in 150 μl of
binding buffer adding 1 μl of DAPI (stock was made of
100μg/μl DAPI (Invitrogen, Life Technologies, Darm-
stadt, Germany) diluted with PBS to 1μg/μl). Cells were
then analyzed by flow cytometry. Both protocols
employed the flow cytometer BD FACS Canto II (BD
Biosciences San Jose, USA) analyzing the results with
the BD FACS Diva software and FlowJo7.6.4. To exclude
cell specific effects of TTP on Colo-357 the cell lines
6606PDA and PaTu8988T were also treated with TTP.
After 10 seconds of TTP treatment cells were analysedafter 1, 6 and 24 hours using the Annexin-V-FITC/
DAPI-staining assay.
TUM-CAM (Tumour-Chorio-Allantoic Membrane) model
Vakzine Lohmann specific pathogen free eggs (VALO
SPF) were obtained from VALO Biomedia GmbH
(Osterholz-Scharmbeck, Germany). After delivery the
eggs were incubated for 6 days at 37 ± 1°C and 65 ± 7%
relative humidity in a small motored breeder (KMB F/2,
Ehret GmbH, Emmendingen, Germany). On day 6 a
small hole (≤1 mm) was punched into the pointed end
of the egg. Then, the hole was closed again with a self
adhesive tape. The eggs were placed with the blunt end,
containing the air cell, facing downwards into the
breeder and incubated for one additional day without
further rotation. On day 7 the egg was carefully opened
at the pointed end and the surface of the CAM was
slightly roughened using a 5x5 mm filter paper
(TISSUE-TEK II, Vogel, Giessen, Germany) saturated
with diethyl ether. Onto this area a silicone ring was
placed, the ring having a 5 mm inner and a 6 mm outer
diameter. Colo-357 cells that had been prepared as
described above, were resuspended at 2x106 cells in 15
μl of a mixture containing 5 μl RPMI-1640 (without
additives) and 10 μl BD Matrigel™ Basement Membrane
Matrix (BD Biosciences, Bedford, USA). Thereafter, this
15 μl tumour cell suspension was carefully filled into the
silicone ring. The defect in the eggshell was closed with
the transparent medical dressing Tegaderm™ (3M
Healthcare, Neuss, Germany) to avoid harmful evapor-
ation of the culture. Eggs were then cultured for an add-
itional 5 days in the breeder. Unfertilized eggs were
excluded from the study.
Plasma treatment in the TUM-CAM model
On day 12 the grown tumours on the CAM were treated
with plasma employing the kINPen09 as described above
using the same time schedule and the same technique of
application (Figure 2). Two control groups (untreated
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above. Following plasma treatment the eggs were cul-
tured for further 48 hours, as described above.
Histology and immunohistochemistry
Tumours were harvested from the CAM using a stand-
ard pointed scalpel, fixed with neutral buffered formalin
over night and embedded in paraffin. 2 μm sections were
cut vertically and mounted on glass slides (SuperFrost®-
Plus, Menzel GmbH & Co. KG, Braunschweig, Germany).
Thereafter, sections were deparaffinized with xylene and
100% ethanol and stained with HE (haematoxylin-eosin)
and PAS (Periodic acid-Schiff reaction) according to
standard protocols. Fertilized eggs were sacrificed by
freezing them at −20°C.
Cell proliferation (Ki-67) was analysed by immunohisto-
chemistry using an automated slide-staining system
(Ventana BenchMark XT, Roche, Mannheim, Germany).
Antigen retrieval was achieved by heat mediated buffer
(pH 9.0) treatment. After rinsing in phosphate-buffered
saline (PBS) endogenous peroxide activity was blocked by
incubation in 3% hydrogen peroxide. After washing, non-
specific binding was blocked with Aurion-BSA (Aurion,
Wageningen, Netherlands). Sections were then incubated
with the primary antibody (anti-Ki-67, monoclonal Mouse-
Anti-Human Ki-67 Antigen Klone MIB1, 1:50 dilution,
DAKO, Hamburg, Germany) for 32 minutes at 37°C.
The primary antibody complex was visualized using a
multimer-technology based detection system (ultraView
Universal DAB, Roche, Mannheim, Germany) according to
the manufacturer’s instructions. Negative controls con-
tained all reagents except the primary antibody.
The slides were examined using a Keyence BZ-9000
microscope (Keyence, Frankfurt, Germany). For deter-
mination of the proliferation index Ki-67 positive cells
were counted using the software dynamic cell count
(BZ-II Analyzer, Keyence, Frankfurt, Germany). Negative
cells were manually counted.
Detection of apoptosis in vivo (TUNEL-Assay)
The number and distribution of apoptotic cells within the
explanted micro tumours was analyzed using the Fra-
gEL™DNA Fragmentation Detection Kit (CALBIOCHEM,
Merck, Darmstadt, Germany) according to the manufac-
turer’s protocol.
Statistical methods
Statistical analysis was performed using GraphPad Prism
(Version 5.01) for Windows software (GraphPad Soft-
ware, San Diego, CA, USA). Results were analyzed using
the Kruskal-Wallis test, Dunn's Multiple Comparison
and the Mann–Whitney test. A p-value below 0.05 was
considered to be statistically significant. If not stated
otherwise the standard deviation is given.Results
TTP induced experimental mild hyperthermia
In culture dishes equipped with a digital thermometer
we found a mild elevation of the original surface
temperature (i.e. 23.7°C) of 2.02°C +/0.56°C after 5 sec-
onds of TTP treatment, of 2.57°C +/−0.23°C after 10
seconds of TTP treatment, and 2.93°C +/−0.40°C after
20 seconds of TTP treatment. Multivariate analysis indi-
cates a significant increase of temperature between 5
and 20 seconds of application (p=0.0019). However, test-
ing within the groups using the non-parametric Mann–
Whitney test we found significant differences between
all groups (p=0.0276 for 5 versus 10 seconds, p=0.0243
for 10 versus 20 seconds) pointing to possible significant
differences if analyzing large sample groups.
Plasma induced cell death in pancreatic cancer cells
in vitro as shown by Annexin-V-FITC/DAPI-staining
Analyzing in vitro grown pancreatic cancer cells 1h after
plasma treatment there was no relevant increase of cell
death using Annexin-V-FITC/DAPI compared to con-
trols (Figure 3A, Table 1). However, a plasma effect on
cell death was detectable 24h after treatment and further
increased up to 72h after treatment levelling off there-
after (Figure 3B-D, Table 1). 24–72 hours after Plasma
treatment we found a significant increase (1.4- to 3.6-fold)
in dead cells compared to untreated or argon gas treated
controls. In addition, we identified a correlation of
increased death rates with the duration of the TTP treat-
ment. In summary, longer TTP application affects cell via-
bility, but the effect becomes visible only after 24-72h
(Table 1). In addition, the murine pancreatic cancer cell
line 6606PDA as well as the human pancreatic cancer cell
line PaTu8988T were analysed in similar experiments
(Additional file 1: Table S1). 6606PDA displayed a high
spontaneous rate of cell death. After TTP treatment there
was a significant increase of cell death compared to con-
trol cells (p=0.0303). Also, PaTu8988T displayed a signifi-
cant increase of cell death following TTP treatment
(p=0.0043).
Plasma treatment induced apoptosis in pancreatic cancer
cells in vitro as demonstrated by propidium iodide cell
cycle analyses
We analysed the mode of cell death by cell cycle ana-
lyses employing propidium iodide. We saw a significant
increase of apoptotic cell numbers after Plasma treat-
ment compared to untreated controls as well as Argon
controls (for all results compare Table 2 and Additional
file 2: Figure S1). Still, there was also a slight but signifi-
cant increase of apoptotic cell numbers after argon gas
treatment compared to untreated controls (p= 0.0013).
Plasma treatment for 5 seconds leads to a significant in-
crease of apoptotic cells which was even higher at 10
Figure 3 Plasma induced cell death in pancreatic cancer cells in vitro as shown by Annexin-V-FITC/DAPI-staining A: after 1h; B: after 24
h; C: after 48h; D: 72 h after TTP treatment.
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plasma treatment the effects reached a peak after 72
hours whereas 5 seconds of plasma treatment peaked
after 48 hours. Also, 10 seconds of plasma treatment
lead to a higher apoptotic rate than 5 seconds of plasma
treatment. However, this was not statistically significant
for the time point 72 hours after plasma treatment
(p= 0.0695). Regarding 20 seconds of plasma treatment
we detected a slight though significant increase of apop-
tosis only after 72 hours compared to the untreated
control (p=0.0143). However, the apoptosis rate after
72 hours following 20 seconds of plasma treatment wasTable 1 Impact of TTP on cell viability of Colo-357 in vitro usi
treatment 1h 24h
control 15.2% (+/−2.8%) 19.3% (+/−1.8%
argon gas 12.5% (+/−1.6%) 20.0% (+/−3.9%
5s plasma 14.1% (+/−3.4%) 44.7% (+/−7.5%
10s plasma 10.5% (+/−4.7%) 50.3% (+/−2.4%
20s plasma 14.2% (+/−5.8%) 69.4% (+/−16.7%
** Indicates significant difference compared to controls (P< 0.01).highly significantly smaller than after 10 seconds of
plasma treatment (p=0.0009).
In summary, plasma treatment significantly induces
apoptosis in pancreatic cancer cells in vitro, with a treat-
ment duration of 10 seconds showing the strongest effect.
Interestingly, 20 seconds of plasma treatment displayed
only a small induction of apoptosis in this setting.
Plasma inhibited proliferation and induced apoptosis in
solid pancreatic cancer tumours of the TUM-CAM model
Microscopical analyses of solid tumours using HE
stained specimens displayed changes within the upper 3ng Annexin-V-FITC/DAPI
48h 72h
) 30.0% (+/−3.9%) 30.1% (+/−4.4%)
) 31.7% (+/−3.4%) 33.0% (+/−4.0%)
)** 42.9% (+/−3.9%)** 49.0% (+/−5.9%)**
)** 50.3% (+/−5.4%)** 59.0% (+/−7.0%)**
)** 73.7% (+/−6.5%)** 78.0% (+/−9.6%)**
Table 2 Plasma treatment induced apoptosis in pancreatic cancer cells in vitro (propidium iodide cell cycle analyses)
treatment 1h 24h 48h 72h
control 1,8% (+/−0.4%) 1,2% (+/−0.2%) 2,5% (+/−0.7%) 2,9% (+/−1.3%)
argon gas 0,7% (+/−0.3%) 2,1% (+/−0.5%) 6,9% (+/−1.9%) 7,9%* (+/−1.9%)
5s plasma 0,4% (+/−0.1%) 13,3%* (+/−6.2%) 31,1%* (+/−2.9%) 26,0%* (+/−6.0%)
10s plasma 1,8% (+/−3.0%) 17,9%* (+/−2.6%) 31,2%* (+/−9.7%) 34,8%* (+/−7.2%)
20s plasma 0,9% (+/−0.2%) 2,8% (+/−1.4%) 6,2% (+/−4.2%) 12,3%* (+/−6.6%)
* Indicates significant difference compared to controls (P< 0.05).
** Indicates significant difference compared to controls (P< 0.01).
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for all TTP application times (Figure 4). Altered cells
showed early microscopic signs of cell death, i.e. cellular
shrinking, a condensed bright eosinophilic cytoplasm
and pycnotic dark small nuclei as a result of chromatin
condensation. No inflammatory reaction was noted. No
effects were observed in deeper layers: Similar to the un-
treated cells in the control, they retained their malignant
phenotype and showed mitotic activity as well as some
spontaneous apoptotic bodies (HE staining, Figure 4).
Then, we analyzed the number of proliferating cells
using the proliferation marker Ki-67. Work-up of total
tumour specimens did not bring up any significant dif-
ferences (Figure 5A, p= 0.9355) between untreated con-
trols (percentage of Ki-67+ cells 77.4 +/− 7.3%), argon
gas controls (78.3 +/− 6.7%,), plasma treatment for 10
seconds (76.6 +/− 7.5%), and plasma treatment for 20
seconds (76.0 +/− 3.1%).Figure 4 Histology using HE-, Ki-67-, and TUNEL-staining of the
TUM-CAM model after plasma treatment. Plasma treatment of 10
seconds and 20 seconds (not shown) led to cell death in the upper
3–5 cell layers (above the dotted line), accompanied by a complete
absence of viable proliferating cells (Ki-67-staining) and a strong
increase in apoptotic activity (TUNEL staining). However, the bottom
cell layers were not affected. One mitotic figure (arrow) and a
spontaneous apoptotic body (arrowhead) of the unaffected deep
layers of a plasma treated tumour as well as an untreated control
tumour were marked. The lower edge of HE- and Ki-67-stains
measure 250μm (original magnification 400x). Original magnification
of TUNEL staining: 200x.However, analyzing the different cell layers of the
micro tumours a significant impact of plasma treatment
onto tumour cells could be demonstrated. Examination
of the tumour layers was then carried out from top to
bottom, the top layers having had direct contact with
the plasma plume. Corresponding to the histology, the
top cell layers displayed almost absent cell proliferation
whereas the bottom layers consisted of strongly prolifer-
ating cells (Figure 4). More specifically, analyzing the
number of proliferating cells in the top 100 μm of the
tumour specimens using the proliferation marker Ki-67
did not bring up any significant differences between un-
treated controls (percentage of Ki-67+ cells 80.9 +/− 13.2%)
and argon gas (71.9 +/− 17.6%, p= 0.2321). Yet, we could
demonstrate a highly significant effect of TTP on cell prolif-
eration in the top layers of the tumours after 10 seconds
TTP (37.7% +/− 14.6%, p< 0.0001) and a significant, but
not additional effect after 20 seconds TTP (37.0% +/− 16.4%,
p< 0.0001, 10 seconds versus 20 seconds p= 0.9359,
Figure 5B).
In addition, corresponding to the absent Ki-67 stain-
ing, TUNEL analyses demonstrated apoptosis of tumour
cells: Untreated control tumours and argon gas only
treated controls displayed only single apoptotic cells
within the top cell layers whereas plasma treated
tumours showed increased zones of apoptotic cell layers
at the top (Figure 4). This was true for 10 seconds of
plasma treatment as well as for 20 seconds of plasma
treatment.
Corresponding to the Ki-67 staining using the TUNEL
method we could demonstrate a highly significant induc-
tion of apoptosis in the top 100 μm of the tumours after
10 seconds TTP (46.2% +/− 13.3%, p< 0.0001). This
could not be further increased after 20 seconds TTP
(44.3% +/− 27.8%, p= 0.0006, 10 seconds versus 20 sec-
onds p= 0.8617, Figure 5C).
Combining the results of HE staining, immunohisto-
chemistry and TUNEL-staining the depth of effective tis-
sue penetration (DETiP) of the plasma jet could be
determined (dotted lines in Figure 4). Following 10 sec-
onds of treatment a DETiP of 36.8 +/− 14.2 μm was
found. This was significantly more compared to changes
of the untreated and the argon gas only treated controls
Figure 5 Impact of TTP in the TUM-CAM model on tumour proliferation and apoptosis A: Using the proliferation marker Ki-67 there
were not significant differences in proliferation of total tumour specimens (Figure 5A, p= 0.9355). B: Analyzing the upper 100 μm of
tumour tissue argon gas had no significant effect on proliferation. 10s TTP highly significantly decreased proliferation (p< 0.0001), with 20s TTP
showing no additional effects (10s versus 20s p= 0.9359). C: TTP induced highly significant apoptosis after 10 seconds (p< 0.0001), and after 20
seconds (p= 0.0006) in the upper 100 μm of the tumour. D: Depth of effective tissue penetration (DETiP) of 20s TTP was up to about 60μm
(p<0.0001), with 10s TTP not being significantly different (p=0.1428).
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p< 0.0001). 20 seconds of treatment showed no signifi-
cant increase (p= 0.1428) of the DETiP to 48.8 +/− 12.3
μm compared to 10 seconds of treatment (Figure 5D).
In summary, TTP induced a significant reduction of
cell proliferation as well as apoptosis in the top cell
layers of solid TUM-CAM tumours. This effect was seen
up to a DETiP of about 60 μm. The in vitro effect of 20
seconds of TTP of non-apoptotic cell death was not
present in solid TUM-CAM-tumours showing mainly
apoptosis.
Discussion
In the search of adjuvant treatment options to de-
crease minimal residual disease after surgery of malig-
nancies in general and pancreatic cancer in particular
tissue tolerable plasmas (TTP) could prove a valuable
tool. In this study we show that TTP causes cell
death in pancreatic cancer cells in vitro. Up to 10 sec-
onds of treatment induced apoptosis whereas longerapplication led to non-apoptotic cell death, all effects
levelling off after about 72 hours after treatment. In
the TUM-CAM model TTP induced apoptosis only in
the top cell layers showing a depth of effective tissue
penetration (DETiP) of up to 60 μm. This represents
the top five cell layers leaving the lower cell layers in-
tact. TTP has also been named non-thermal [19] or
cold plasma [20]. Yet, we experienced small but meas-
urable increases of the temperature following TTP
treatment. However, even after 20 seconds of TTP ap-
plication the temperature increased by a maximum of
only 3.5°C. Assuming a body temperature of 37.0°C
the expected maximum tissue temperature even after
20 seconds of TTP application would not exceed
41°C. This mild TTP induced elevation of tissue
temperature is rather unlikely to exert negative effects
on surrounding healthy tissues in tumour patients [21].
Similar in vivo results in mice growing subcutaneous
melanomas were demonstrated by Keidar et al. in
2011 [21].
Partecke et al. BMC Cancer 2012, 12:473 Page 8 of 10
http://www.biomedcentral.com/1471-2407/12/473The treatment of pancreatic cancer cells in vitro using
TTP induced non-apoptotic cell death as well as apop-
tosis. To exclude cell line specific effects of the pancre-
atic cancer cell line Colo-357 we tested two more
pancreatic cancer cell lines (the mouse pancreatic cancer
cell line 6606 PDA and the human pancreatic cancer cell
line PaTu8988T) in vitro. In fact similar effects could be
demonstrated in both cell lines confirming the results of
Colo-357. Comparable to our results in the three differ-
ent cell lines Kim et al. found cell specific differences in
the plasma effects, too. The colon cancer cell lines
SW480 and LoVo displayed a higher resistance to
plasma treatment than HCT-116 cell [19].
This effect was best seen after 10 seconds of TTP ap-
plication levelling off after about 72 hours following the
application. Similar effects of plasmas have been
described for lung cancer cells and melanoma cells con-
cerning apoptosis [15,20]. However, non-apoptotic cell
death was not found by Kim et al. [20] applying up to 10
seconds of plasma in vitro whereas Keidar et al. [21]
described in vitro findings comparable to ours. In
addition, Keidar et al. did not describe any relevant
damages of non-malignant cells in an in vivo tumour
model applying 5 minutes of plasma. Yet, the exact in-
duction mechanisms of apoptotic or non-apoptotic cell
death were not analyzed. Yan et al. could recently dem-
onstrate that the increased concentrations of nitric oxide
(NO), reactive oxygen species (ROS), and lipid peroxide
during the plasma treatment correlated with the increas-
ing number of dead tumour cells [22]. Ahn et al. could
demonstrate that Plasma induces apoptotic apoptosis via
ROS and dysfunction of mitochondria membranes in the
human cervical carcinoma cell line HeLa [23]. In con-
trast, cotreatment with scavengers of ROS mitigated the
apoptotic effect. Also, the treatment with caspase 3 and
9 inhibitors had extenuating effects on plasma-induced
cell death further confirming the involvement of mito-
chondria in plasma-induced apoptosis. Furthermore, a
caspase 8 inhibitor had little effect on plasma-induced
apoptosis, suggesting that plasma-induced apoptosis is
not mediated through activation of the extrinsic apop-
totic pathway involving death receptors. However, the
specific step in the intrinsic apoptotic pathway affected
by Plasma treatment via ROS has not been identified.
Depolarization of the mitochondria membrane potential
may play a central role, but further studies are necessary
in this respect.
Using the TUM-CAM model we have not yet analyzed
non-malignant cells but could show that solid tumour
cells underwent apoptotic cell death up to a DETiP of
60 μm. These results point to a fundamental difference
of the effects of TTP in vitro and in vivo. 10 seconds of
TTP initially represent a sub-lethal dose of plasma
in vitro yet initiate apoptosis in most or all tumour cells.20 seconds of TTP induce apoptosis only in a small per-
centage of tumour cells irreversibly damaging the major-
ity of tumour cells by non-apoptotic cell death. In
contrast, applying TTP in vivo in the TUM-CAM model
we have only been able to demonstrate apoptotic cell
death in tumour cells so far.
Taken together our results suggest a possible applica-
tion of TTP in pancreatic cancer surgery. Since we have
demonstrated a DETiP of up to 60 μm leaving lower
tumour layers intact not changing their rate of prolifera-
tion the treatment of solid tumours, as already suggested
by other authors [21,24], may not significantly improve
survival rates. Therefore, we suggest the intra-operative
use of TTP in surgical patients to treat possible minimal
residual disease after resection. We suggest that pancre-
atic cancer patients could greatly benefit from this treat-
ment option since tumours of many patients are
resectable but show minimal residual disease of retro-
peritoneal tissues and major supplying mesenteric ves-
sels [3] which is an independent prognostic factor for
poor survival [25]. TTP treatment could destroy these
tumour cells leaving the non-malignant surrounding tis-
sues intact since several groups have described more
pronounced plasma effects on cancer cells than on stro-
mal cell, including fibroblasts [15,20]. Keidar et al.
detected “plasma selectivity” for murine melanoma can-
cer cells while murine macrophages were not affected
[21]. However, the reason for stromal cells being more
resistant to plasma treatment than cancer cells is still
unknown. It remains an important part of the ongoing
research of many investigators.
Furthermore, additional applications could be carried
out for malignant tumours of the liver involving central
non-resectable liver vessels and bile ducts as well as cen-
tral lung tumours involving non-resectable vessels and/
or bronchi. Finally, TTP and chemotherapeutic drugs
may have synergistic effects either using low dose che-
motherapies before surgery and intra-operative TTP
treatment or vice versa [26].
Conclusions
These promising results require the adaptation of our
plasma source to an improved clinical application since
the plasma plume of the kinPen09 only allows the treat-
ment of small tumours and/or small tissue areas. A fan-
like applicator would be ideal for these purposes. Also,
the composition of the effective components of the TTP
ought to be evaluated for their effectiveness to optimize
their synergistic apoptotic actions. This applies to the
modifiable components (electrons/ions, free radicals,
electromagnetic particles, UV radiation and the carrier
gas) of the TTP. Ongoing in vivo experiments will fur-
ther evaluate treatment options of TTP in an orthotopic
syngeneic mouse model of pancreatic cancer [17,27].
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Additional file 1: Table S1. The murine cell line 6606PDA and the
human cell line PaTu8988T were treated with TTP using the same set up
as for Colo-357 (Table 1). 6606PDA as well as PaTu8988T showed a
significant increase in cell death after TTP treatment (p=0.0303 and
p=0.0043, respectively).
Additional file 2: Figure S1. Cell cycle analyses: Percentage of
apoptosis as sub-diploid peaks left to G0/G1-peak. Apoptotic cells 72
hours after TTP versus control and argon gas; example of 5 independent
experiments.
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